# ImmunAbs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunabs

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.immunabs.com/
- Total disclosed funding: $79M
- Latest round: Series C (Jul 1, 2026)
- Investors on record: 12

## About

Founded in 2017, and based in Seoul, South Korea, ImmunAbs Inc. is a drug development specializing company that provides various antibody screening and engineering technologies such as phage display, single B cell cloning, and bispecific antibody development. In July 2026, ImmunAbs Inc. raised KRW 38 billion in series C funding from new investor HANIL VC, with participation from returning investors CKD Venture Capital, Seoul Investment Partners, D3 Jubilee Partners, and Daekyo Investment.

ImmunAbs Inc. offers antibody screening and engineering technologies such as phage display, single B cell cloning, and bispecific antibody development. It offers treatment for autoimmune diseases.

The company plans to use the July 2026 funding for for global clinical trials.

## Funding rounds

- Series C, Jul 1, 2026, $25M — CKD Venture Capital, Seoul Investment Partners, Daekyo Investment, D3 Jubilee Partners, HANIL VC
- Series B, Nov 30, 2022, $10M — CKD Venture Capital, Seoul Investment Partners, Daekyo Investment, DT&Investment, Magna Investment, Hana Securities, D3 Jubilee Partners
- Series A, Oct 28, 2020, $44M — Seoul Investment Partners, Daekyo Investment, Mirae Asset Venture Investment, Korea Asset Investment Securities, Magna Investment, NICE Investment Partners, D3 Jubilee Partners, ST Capital

## Investors

- Seoul Investment Partners (https://capitalatlas.ai/funds/seoul-investment-partners) — Series A, Series B, Series C
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series A, Series B, Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series A
- Korea Asset Investment Securities (https://capitalatlas.ai/funds/korea-asset-investment-securities) — Series A
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series A, Series B
- NICE Investment Partners (https://capitalatlas.ai/funds/nice-investment-partners) — Series A
- D3 Jubilee Partners (https://capitalatlas.ai/funds/d3-jubilee-partners) — Series A, Series B, Series C
- ST Capital (https://capitalatlas.ai/funds/st-capital) — Series A
- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series B, Series C
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series B
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series B
- HANIL VC (https://capitalatlas.ai/funds/hanil-vc) — Series C